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MICROABSTRACT 
Weight variations during treatment are associated with poor prognosis for early breast cancer 
patients. The study of body composition during adjuvant treatment is the key to 
understanding this interaction. With a median follow up of 3 years post-chemotherapy, our 
results show a small weight gain, but highlights that initial fatness in postmenopausal breast 
cancer patients promotes longitudinal 3-years weight gain. 
ABSTRACT 
Purpose: Weight change during adjuvant treatment for early breast cancer is associated with 
poor prognosis. The long-term evolution of body composition during adjuvant treatment for 
breast cancer, particularly endocrine therapy, is not well known and new data on this topic is 
required. The present study assesses the evolution of weight and body composition among 
33 postmenopausal breast cancer patients currently treated with endocrine therapy after 
standard adjuvant chemotherapy including Taxanes. 
Patients and Methods: Dual-Energy X-ray Absorptiometry (DXA) was used to measure fat 
and lean body mass. Body water was assessed by multifrequency bioelectrical impedance 
analysis. The HAD questionnaire and the short version of the IPAQ were also administered. 
Results: During endocrine therapy, 15.2% (n=5) of the population lost weight and 36.4% 
(n=12) gained weight. The overall average gain was 2.0kg ±5.5 (p= 0.04). During this period, 
fat mass, lean body mass and body water increased. Factors linked to fat mass gain are 
excess fat mass (≥36%) before treatment and weight loss during chemotherapy. In the 
overall period of adjuvant cancer treatment, 30% of the population gained more than 5% of 
their initial weight. The average gain was the same as during the endocrine therapy period 
(2.0kg ±5.4; p=0.031) and was characterized by an increase in total lean body mass, mainly 
localized in the trunk region. 
Conclusion: Endocrine therapy appears as a pivotal period in weight and body composition 
management. Overfat/obese patients and those who lose weight during chemotherapy are 
more subject to weight and fat mass gain during endocrine therapy. 
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INTRODUCTION 
Excess weight is well known to be a risk factor in breast cancer 1,2 and at the time of 
diagnosis is considered as a poor prognosis factor, with higher risks of recurrence and 
mortality 3,4. There is also substantial evidence that weight change during cancer treatment 
could be associated with poorer prognosis among women with early breast cancer, whether 
weight gain or weight loss 3,5.  
Mechanisms to explain the adverse effect of weight variation have not been clearly identified 
but two hypotheses have been proposed 6: (i) adipose tissue is a source of oestrogen 
production and becomes the main source of oestrogen after the menopause, so a higher 
circulating oestrogen level associated with abdominal obesity is observed 7, especially in 
oestrogen-dependent postmenopausal cancer 1,3,8 and (ii) adipose tissue induces metabolic 
disturbances in the insulin and adipokine pathways.  
As fat mass gain is the first hypothesis explaining the pejorative impact of weight gain, the 
evaluation of body composition is more appropriate than weight assessment. Weight and 
body composition variations among postmenopausal breast cancer patients have mainly 
been studied during chemotherapy. Water retention is one of the side effects of modern 
chemotherapy, particularly Taxane-based chemotherapy, 9,10 and it is also thought that 
weight gain during chemotherapy results from greater water gain than fat mass gain 
(NCT01506466, under submission). These results could explain the absence of relationship 
between weight gain and poor prognosis shown by recent studies 11,12.  
While several studies found that a fairly small weight gain occurred during endocrine 
therapy 13–16, a recent retrospective chart review 17 shows that postmenopausal breast cancer 
survivors do not necessarily gain weight after two years of endocrine therapy. But little 
information is available about the impact of subsequent adjuvant treatment, among which 
endocrine therapy, on long-term body composition. In a double-blind placebo-controlled 
study with 24 months follow-up, an increase in lean body mass was observed among 
patients on aromatase inhibitors (AI) compared to those not treated with AI 13. In the same 
way, a randomized trial showed that a switch from tamoxifen to Exemestane induced body 
composition modification in overweight or obese patients, with a decrease in fat mass and an 
increase in the fat-free mass/fat mass ratio in the group of patients receiving AI, compared to 
the continued tamoxifen group 18,19. In another study, after at least 6 months of AI, the total 
abdominal adipose tissue increase was about 9,1% in all subjects whatever the weight 
variation, reflecting an increase in the volume of visceral abdominal tissue 20. This study 
highlights the importance of studying body composition, because weight variations do not 
reflect body mass distribution. 
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Body composition variation seems to differ markedly according to the type of 
treatment (chemotherapy, hormonotherapy) and for patients treated with both we do not 
know the impact of previous variations in weight and body composition under chemotherapy 
on variation during hormonotherapy.   
To the best of our knowledge, no longitudinal study of body composition has been 
conducted on a cohort of early breast cancer patients treated with adjuvant chemotherapy, 
radiotherapy and then endocrine therapy. The aim of this study was to characterize the 
evolution in weight and body composition of postmenopausal breast cancer patients treated 
with adjuvant endocrine therapy (for more than one year) after chemotherapy. Factors 
influencing to these parameters during endocrine treatment, will also been investigated. 
 
PATIENTS AND METHODS 
Study population  
From July 2015 to November 2016, 33 patients were enrolled in the MetaCa2 trial 
(NCT02509871) (see Figure 1). This study was approved by competent authority and the 
local ethics committee. All participants signed informed consent. All of them had participated 
in the previous MetaCa trial (NCT01506466) which investigated the evolution of body 
composition and related factors 1 month (T1) and 6 months (T2) after chemotherapy 
treatment (results under submission). Patients were invited to participate in the Metaca2 
study only if they were currently receiving endocrine therapy. All patients were post-
menopausal, and patients with a cancer relapse or another cancer were excluded.  
Study outcomes 
Data obtained in the Metaca study (T0-T1-T2) for the patients participating in the Metaca2 
study were used for the longitudinal comparison of weight, body composition, 
anxiety/depression and time spent sitting. All measurements in the Metaca2 study were 
performed during a follow-up visit after a median time of three years following initiation of 
endocrine therapy [1,8 ; 4,5] (T3; see Figure 2 : study design). The parameters were 
assessed according to the same methods as in the MetaCa study (NCT01506466; under 
submission).  
Body weight 
Body weight was measured to the nearest 0.1 kg in underwear and without shoes. The 
National Cancer Institute (CTCAE v.4.0) defines weight variation as a gain or loss greater 
than 5% of initial weight. 
Body composition 
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Dual-Energy X-ray Absorptiometry (DXA) (Hologic 94 Discovery QDR; Hologic Inc, Waltham, 
Massachusetts) was used to measure fat mass and lean body mass and their distribution. A 
multifrequency bioelectrical impedance analysis (Bodystat Quadscan 4000) was used to 
evaluate total body water. To assess central fat distribution, waist circumference was 
measured to the nearest 0.5 cm with a standard tape measure placed between the lowest rib 
and the iliac crest, in standing position. In the same way, hip circumference was measured 
using standard tape placed horizontally on the widest point on the hip.  
Physical activity  
The short version of the International Physical Activity Questionnaire (IPAQ) was completed 
to evaluate time spent sitting per day in minutes and physical activity expressed in metabolic 
equivalent (MET) × minutes per week 21. 
Anxiety and depression  
Two validated self-administered questionnaires were used to evaluate anxiety and 
depression (Hospital Anxiety and Depression scale - HADs). The interpretation of this scale 
is based on the score: 7 or less means non-case, between 8 and 10 corresponds to a 
doubtful case and more than 11 reflects a definite case 22. 
Statistical analyses 
SEM software was used to perform data-management and statistical calculations 23. Patient 
characteristics were described using mean ± standard deviation or median and [range] in 
case of non-Gaussian distribution, for quantitative parameters. For categorical parameters, 
counts and frequencies were calculated by category. The evolution of measures over time 
was tested using two-way ANOVA. Statistical relationships between pairs of variables where 
one variable was categorical were studied using Student's t-test, ANOVA (or Mann-Whitney 
U-test, Kruskal-Wallis H-test in case of non-Gaussian distributions and/or heteroscedasticity). 
When both variables were quantitative, Pearson's correlation coefficients (or Spearman rank 
correlations, if distributions were non-Gaussian) were calculated. All tests were two-sided 
and the standard significance threshold, p ≤0.05, was used. Univariate analysis was 
performed using ANOVA to determine the parameters associated with weight and body 
composition variations (fat mass, lean body mass, body water). The parameters tested as 
potentially correlated with these variations between T2-T3 were age at diagnosis, age of 
menopause, medical history (arterial hypertension, smoking, hypothyroidism, lifetime weight 
variation, ongoing treatments,  change in endocrine treatment), pre-adjuvant treatment 
factors (fat mass percentage, waist and hip circumference, W/H ratio, android fat 
mass/gynoid fat mass ratio, lean body mass), variation of other parameters for each period of 
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treatment (variation in weight, fat mass, and time spent sitting). Concerning T0-T3 variations, 
the same parameters were tested and body water variations for the different periods in the 
study were added. 
Multivariate analysis using MANOVA was then performed, comprising all the factors selected 
in the previous univariate analysis (p ≤ 0.05).  
We decided to divide our population into two groups according to the body fat ranges 
proposed by Gallagher and colleagues 24, more precise than a classification by BMI, and 
taking into account the pre-chemotherapy fat mass value of patients from MetaCa study. 
(DXA, T0). We classified each patient in the normal fat mass subgroup (fat mass <36%) or 
the overfat/obese subgroup (≥36% fat mass), according to initial fat mass percentage and 
adjusting for the age.  
 
RESULTS 
Patient characteristics 
Patient and treatment characteristics are summarized in Table 1. On the basis of the pre-
adjuvant treatment fat mass percentage (T0), 48.4% of the population was classified as 
having normal fat mass, 36.4% (n=12) as overfat and 15.2% (n=5) as obese. At the T3 
evaluation, the median duration of endocrine therapy was 3 years [1.8; 4.5]. The large 
majority of patients were currently treated with aromatase inhibitors (97%). Only six patients 
had switched to a new endocrine treatment for reasons of tolerance: 2 from Tamoxifen to 
aromatase inhibitor and the others from one aromatase inhibitor to another. 
 Weight variations  
During endocrine therapy (Between T2 and T3) 
On average across the sample, a significant weight gain occurred after initiation of adjuvant 
antihormonal therapy (+2.0kg ±5.5) (p=0.04), i.e. between T2 and T3. Among these patients, 
15.2% (n=5) lost weight (-4.4kg ±0.9 i.e. -7% ±1.4 of their body weight), and 36.4% (n=12) 
gained weight (+8.3kg ±3.6 i.e. 12.1% ±7%). In relation to the pre-adjuvant cancer treatment 
fat mass percentage (T0), only the subgroup of overfat/obese patients underwent a 
significant weight change between T2 and T3 (p<10-7). In this subgroup, the average weight 
gain was 3.8kg (±5.6) (p=0.012). 
Univariate analyses showed that the weight gain between T2 and T3 depended on four 
factors: fat mass class (p=0.014), waist (p=0.043) and hip circumference (p=0.016) at T0, 
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and weight variation during chemotherapy (p=0.0059). In multivariate analysis on these 
parameters, two still had a significant impact on the variation of weight between T2-T3. 
Firstly, weight variation during chemotherapy period (p=0.000059) and secondly the initial fat 
mass class (p=0.00052). 
 For the overall period of treatment (between T0 and T3) 
Over the full period of cancer treatment, from the pre-adjuvant cancer treatment (T0) to a 
median time of three years of endocrine therapy (T3), the average weight increase was 
about 2.0kg (±5.4) [-5.7; 22.2] (p=0.031) corresponding to a gain of 2.9% (±7.9) compared to 
weight at T0. Nine percent (n=3) of the population lost more than 5% of their pre-adjuvant 
treatment weight with an average loss of 5kg (±0.6), i.e. 8.3% (±1.7). Thirty percent (n=10) 
gained more than 5% of their initial weight with an average weight gain of 7.9kg (±5.9), i.e. 
11.6% (±8.4), and 61% remained stable (n=20).  
The longitudinal evolution of weight according to the pre-adjuvant treatment fat mass 
percentage is presented in Figure 3. Weight was not significantly impacted by the different 
periods of treatment from T0 to T3 (only a trend in the effect of time is observed p=0.07). The 
initial fat mass percentage was significantly related to the longitudinal evolution of weight 
(p=0.033). In relation to initial fat mass percentage, while normal fat mass patients showed 
relative weight stability, overfat/obese patients lost weight during the chemotherapy period 
and then gained weight up to T3.  
Several factors are associated with weight gain in the overall period of study (T0-T3), i.e. 
from pre-adjuvant treatment to a median time of three years after initiation of endocrine 
therapy. It was affected by age of menopause (p=0.033), whereby women menopaused 
before the age of 52 gained more weight than those menopaused later. Weight gain greater 
than 5% between T2 and T3 (p=0.0003), increase in fat mass between and T2 and T3 
(p=0.031) and increase in body water between T2 and T3 (p=0.034) were also significantly 
linked to weight gain between T0 and T3. Of these four significant parameters identified in 
the univariate analyses, three still retained significance in multivariate analyses. In 
descending order of probability, we find weight variation between T2 and T3 (p=0.0015), fat 
mass variation between T2 and T3 (p=0.026), and age of menopause (p=0.04). These three 
factors explain 41% of weight variation across the period of study (T0-T3). 
Body composition variations  
Changes in fat mass, lean body mass and body water 
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Body composition changes are presented in Table 2. The variations during the period of 
endocrine therapy (T2-T3) are presented in Figure 4. For the overall population, a significant 
gain in total fat mass is observed (1.8kg ±3.8; p=0.0073) mainly localized in the abdominal 
region (1.4kg ±2.2; p=0.00031). A significant increase in both total and trunk lean body mass 
also occurred, corresponding to a gain in body water. No significant variations were observed 
in the subgroup of normal fat mass patients. Overfat/obese patients, for their part, saw an 
increase in their total and trunk fat mass of about 2.8kg (±3.5) (p=0.0054) and 2.2kg (±2) 
(p=0.00067) respectively. They also gained total (1.4kg ±2.2; p=0.024) and trunk (1.4 ±1,6; 
p=0.0048) lean body mass, corresponding to a gain in body water (1.4kg ±1.6; p=0.0052) at 
intracellular level (1.5 ±2.6; p=0.047).  
Fat mass gain between T2 and T3 was linked to the initial fat mass class (p=0.053), weight 
variation between T0 and T1 (p=0.00031) and time spent sitting (T1-T2) (p=0.05). All these 
parameters were still significant in multivariate analyses. These factors explain 44% of fat 
mass variation between T2 and T3, i.e. from six month post-chemotherapy to a median time 
of three years post initiation of endocrine therapy. Concerning body water variation between 
T2 and T3, when the parameters identified as significant in the univariate analyses (i.e. pre-
adjuvant treatment fat mass class and weight variation between T0-T1) were tested in 
multivariate analyses, we did not find any variable implicated in the variation. 
Over the whole period of treatment (T0-T3), body composition in the overall population 
(n=33) is characterized by a significant increase in total lean body mass (+1.5 ±3.2; 
p=0.0083) especially in the trunk region (+0.85kg ±2; p=0.015). These variations reflect the 
variation occurring in the subgroup of overfat/obese patients where a gain in total lean body 
mass (2.1kg ±3.7; p=0.034) and trunk lean body mass (1,3kg ±2.3; p=0.034) was observed. 
No variation in fat mass was observed in the overall population nor in the subgroups of 
patients. 
Lean body mass variation between T0 and T3 was linked to age of menopause (p=0.0084), 
initial fat mass percentage (p=0.043), weight variation between T2-T3 (p=0.02), fat mass 
variation between T0-T1 (p=0.0.035) and body water variation between T2-T3 (p=0.000076). 
Multivariate analyses revealed that four factors were significantly associated with lean body 
mass variation between T0-T3: weight variation between T2-T3 (p=0.0009), age of 
menopause (p=0.0026), body water variation between T2-T3 (p=0.0067) and finally fat mass 
variation during the chemotherapy period (T0-T1) (p=0.03). More than half of the lean body 
mass variation between T0 and T3 is explained by these factors (57%). 
Changes in waist and hip circumference 
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During the T2-T3 period, there was no significant difference in the waist to hip ratio (W/H 
ratio) (p=0.55), whether in the overall population or in the different subgroups. Nevertheless, 
during this period, significant increases in both waist and hip circumferences are observed 
for overfat/obese patients, respectively +7.5cm ±7.5 (p=0.0017) and +4.8 ±4.6 (p=0.0012).  
Overall, no significant change was observed in the evolution of the W/H ratio. Nevertheless, 
the subgroup of overfat/obese patients had a W/H ratio of over 0.85, meaning android 
obesity, throughout the study (from T0 to T3). In the same way, from the beginning of the 
study to the last follow-up, their waist circumference was over 90 cm, also characterising 
android obesity. Their waist circumference increased about 8.5cm (±7.8) (p=0.0013) between 
T0 and T3.  
Analysis of results on the short version of the IPAQ questionnaire  
Overall, time spent sitting increased by about 112 minutes (±154) on average from pre-
adjuvant treatment (T0) to a median time of three years post initiation of endocrine therapy 
(T3) (p=0.00048). More precisely, between T2 (six month post chemotherapy) and T3, an 
increase of about 100.4 minutes (±166) (p=0.0042) was observed. Regarding subgroups, 
only overfat/obese patients exhibited significant variations in their time spent sitting in these 
two periods, i.e.T0-T3 and T2-T3. Nevertheless, in our population at T3 evaluation, 91% 
(n=30) of the patients reported more than 750 MET.min/week and only 6% reported less than 
450 MET.min/week (n=2).  
Analysis of the HAD questionnaire  
In the overall population, at T3, we found that 21.2% (n=7) of the patients had an anxiety 
score between 8 and 10 and 33.3% (n=11) had a score over 11 revealing a state of anxiety. 
Concerning the depression score, 85% (n=28) of the population had a score under the 
threshold and 6% (n=2) had a score reflecting depressive symptoms. However no significant 
changes in anxiety and depression levels were observed over the period of treatment.  
 
DISCUSSION 
This trial assessed the body composition evolution among postmenopausal breast cancer 
patients after a median time of three years of endocrine therapy post-chemotherapy, and 
studied factors implicated in variations observed.  
After a median follow-up of 3 years of endocrine therapy (T2-T3), we found a mean weight 
gain of about 2.0kg (±5.5). This result is consistent with previous studies, which reported a 
weight gain under endocrine treatment of around 2kg. Baum and colleagues 25 studied 
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weight variations over 24 months in three groups of postmenopausal patients treated with 
either anastrozol alone, or tamoxifen or a combination of both, and observed a similar gain in 
the 3 groups with a mean of 1,65 kg over the 24 months of follow-up. Another study 13 
showed a gain of 1,76 ±0.66 kg in postmenopausal women treated with aromatase inhibitor 
as well as in those who were not treated with aromatase inhibitor over 24 months. 
Heideman’s team 26 evidenced a mean weight gain of 2,6 ±6 kg in patients treat combined 
systemic treatment (chemotherapy + endocrine therapy) one year post diagnosis. We 
showed that weight loss during chemotherapy (T0-T1) and a high initial fat mass percentage 
were the strongest parameters associated with the weight gain during endocrine therapy. 
This is in accordance with a recent review, which highlights that weight gain in the first two 
years of endocrine therapy is associated with weight loss between diagnosis and the 
beginning of endocrine therapy 17.  
In our study, this weight gain during endocrine therapy corresponds to an increase in fat 
mass mainly located in the abdominal region and an increase in lean body mass mostly 
corresponding to body water. Concerning lean body mass, in the study by Battisti and al., 20 
patients treated with aromatase inhibitor showed an increase in lean body mass and in the 
lean body mass/fat mass ratio. Similar results were found in a double-blind, placebo-
controlled randomized trial, with 24 months follow-up. Only a gain in lean body mass was 
observed, and no changes in body fat mass were reported in the group of patients treated 
with aromatase inhibitors compared to those who were not 13. The authors explain that this 
lean body mass gain can be induced by the inhibition of aromatase, leading to an 
accumulation of androgens that are known to be linked to muscle protein synthesis. 
Nevertheless, both of these studies evaluated body composition only from DXA and did not 
perform bioelectrical impedance analysis, so that no conclusions were drawn on body water. 
Our study shows that the gain is mainly due to an increase in intracellular water retention. In 
addition, as previously described by Battisti and colleagues 20, variation in abdominal fat 
mass distribution is observed in women under aromatase inhibitor treatment, and particularly 
an increase in visceral adipose tissue (i.e. contained in the abdominal cavity). With a follow-
up of around 4 years after initiation of endocrine therapy, the authors observed an increase 
in total abdominal adipose tissue of 9.1%, which is equal to the increase in total fat mass 
percentage observed in the present study after endocrine therapy initiation (T2-T3). 
Nevertheless, we found a greater increase than in this study (17.5%) over 36 months follow-
up.  
During endocrine therapy, weight loss during chemotherapy, initial fat mass class and 
increase in the time spent sitting after diagnosis are the main parameters associated with fat 
mass gain. It has been shown that treatments exacerbate the decrease in physical activity 27–
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29 and increase time spent sitting 30. However, the literature reports that more than the half of 
the patients are insufficiently active at the time of diagnosis 29,31. In our study, after a median 
time of three years post initiation of endocrine therapy (T3), we found that the majority of the 
population had a level of physical activity of over 750 MET.min/week. International 
recommendations for physical activity advise 150 minutes/week of moderate activity (3 to 6 
MET/week) i.e. between 450 and 750 MET.min/week 32. These recommendations have been 
extended to breast cancer patients 33–35 and many studies have shown the benefits for 
patients of staying active during treatment, in particular in reducing the risk of death and 
relapse 36. Furthermore, being active is of particular interest in reducing fat mass and 
improving muscle strength 37–39. It is also important to underline that reducing sitting time is 
associated with a decrease in mortality 40–43. More precisely, it has been shown that the 
replacement of one hour sitting by one hour standing per day significantly reduces mortality 
43. Currently, it is really important to establish physical activity programmes during treatment 
to encourage patients to comply with international recommendations, particularly in the 
subpopulation that we have identified. Indeed, as demonstrated in our study, patients with a 
high initial fat mass percentage are the most exposed to weight variation in the course of 
treatment, and especially to fat mass gain in the long term, which accumulates predominantly 
in the trunk region suggesting accumulation of visceral adipose tissue which is associated 
with cardio-metabolic complications 6,20,44. 
Several studies 26–28 have described a weight gain in the year following diagnosis, but none 
according to the sequence of treatment. On the over period of evaluation in this study (from 
the initiation of chemotherapy to the 3 years of endocrine treatment i.e. 3 years and 6 months 
of follow-up), we observed a weight gain of 2.0kg and this gain was principally due to the 
weight gain during endocrine therapy. In our study, we did not find any weight gain during the 
first 9 months after adjuvant treatment initiation in our MetaCa cohort (NCT01506466) (T0-
T2: from initiation of chemotherapy to 6 months after the end). The weight gain occurred later 
i.e. during endocrine therapy, and corresponds to a fat mass gain. Endocrine therapy 
appears to be a pivotal period to explain weight change during endocrine therapy.  
Several studies have highlighted that weight variations, either gains or losses, during 
chemotherapy are implicated in poorer prognosis 5,27,45,46. The mechanisms of a pejorative 
impact of weight gain could be explained by the fat mass gain, but for weight loss, they are 
not clear. Our study shows fat mass gain consecutive to a weight loss during the 
chemotherapy period. We can hypothesise that losing weight during chemotherapy is 
associated with a gain in fat mass during endocrine therapy more particularly for patients 
with fat mass excess (overfat/obese). Previous weight loss could be linked to the later gain 
through fat overshooting as previously reported in energy restriction 47. Remarkably, during 
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endocrine therapy, we observed a gain in fat mass particularly in the trunk region. Abdominal 
fat mass excess is well known to be associated with poor prognosis for breast cancer 
patients 48–50. One of the mechanisms explaining this relationship is that visceral adipose 
tissue is associated with metabolic syndrome 20 and with insulin resistance 6,44.  There is a 
need to conduct long-term studies on a larger population to explore this hypothesis. 
 
CONCLUSION 
The effects of adjuvant endocrine therapy on body composition among postmenopausal 
breast cancer survivors were studied in this trial. With three-year hindsight after endocrine 
therapy initiation, a fairly small weight gain is observed but it is associated with changes in 
body composition distribution. Indeed, patients gain in fat mass particularly in the trunk 
region. Overfat/obese patients and those who lost weight during chemotherapy were more 
subject to weight and fat mass gain during endocrine therapy.  
CLINICAL PRACTICE POINTS 
 While several studies have described weight and body composition variation during 
chemotherapy for early breast cancer, to the best of our knowledge, ours is the first 
longitudinal study conducted on a cohort of postmenopausal patients treated with 
chemotherapy, radiotherapy and endocrine therapy. 
 Only a fairly small weight gain is observed with a follow-up of 3.6 years post 
chemotherapy, but it corresponds to the weight gain observed during the endocrine 
therapy period. 
 Overfat/obese patients are more susceptible to a fat mass gain during endocrine 
therapy than normal fat mass patients. This highlights the interest of nutritional and 
physical activity interventions focusing also in reducing time spent sitting in this 
population at the beginning of treatment. 
 Further longitudinal cohort studies are needed to confirm these results. 
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TABLES CAPTIONS 
Table 1: Characteristics of patients  
Abbreviations: BMI = body mass index; FEC = 5fluorouracile, epirubicin and 
cyclophosphamide 
 
Table 2: Body composition variations 
Weight variation was defined by a gain or loss greater than 5% of initial body weight. T0-T3 
covers the entire period of the study, from pre-adjuvant treatment to a median follow up of 44 
months including endocrine therapy. T2-T3 corresponds to a period of 34 months. Endocrine 
therapy was started on average 3 months before the T2 measurement point. SD: standard 
deviation; Bold values correspond to p<0,05. 
 
FIGURES CAPTIONS 
Figure 1: Flow chart 
Six patients from the previous study, MetaCa, are not currently treated with endocrine 
therapy and three had no DXA measures at T0 or T2, and/or they did not meet selection 
criteria. Of the forty-three potential inclusions, nine patients refused to participate in the study 
and one patient had a cardiac device that prevented the DXA measure, corresponding to a 
non-inclusion criterion. 
 
Figure 2: Study design 
All patients were included in the MétaCa2 trial on the occasion of a follow-up visit for their 
endocrine therapy treatment. All the measurements performed at T3 had already been 
performed at T0, T1 and T2 (MétaCa trial). RTX: Radiotherapy; DEXA: Dual-energy Xray 
absorptiometry; IPAQ: International physical activity questionnaire; HAD: Hospital anxiety 
and depression scale 
 
Figure 3: Percentage of weight variation according to initial fat mass percentage groups 
Overfat/Obese patients exhibited more weight changes across the different periods in the 
study than normal fat mass patients. The difference between the curves is significant (p= 
0.033) but no time effect is evidenced (p= 0.07).  
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Figure 4: Body composition variations between T2 and T3  
Only the subgroup of overweight/obese patients exhibited statistically significant variations in 
body composition in the trunk region compared to the healthy subgroup. *Statistically 
significant (p<0,05). Mean ± SEM. 
 
TABLES 
Table 1 
General characteristics 
Age at T3 (years), median   64 [55; 75] 
Mean weight at T3 (kg) 70 ± 15 
Mean BMI at T3 (kg/m²), n (%) 
BMI < 25 
25 ≤ BMI < 30 
BMI ≥ 30 
26,9 ± 6,4 
16 (49) 
8 (30) 
9 (21) 
Age at menopause (years), median [min; max] 51 [45; 59] 
Initial fat mass percentage (T0), n (%)  
Normal fat mass : < 36% 
Overfat/Obese : ≥ 36 % 
 
16 (48,5) 
17 (51,5) 
Tumor characteristics 
pT, n (%) 
T1  
T2 
T3 
 
24 (72,7) 
8 (24,2) 
1 (3) 
pN, n (%) 
N0 
N1 
N2 
N3 
 
20 (60,6) 
10 (30,3) 
2 (6,1) 
1 (3,0) 
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Oestrogen receptor, n (%) 
positive 
negative 
 
33 (100) 
0 (0) 
Progesterone receptor, n (%) 
positive 
negative 
 
28 (84,8) 
5 (15,2) 
HER2 status, n (%) 
positive 
negative 
 
4 (12,1) 
29 (87,9) 
SBR grade, n (%) 
II 
III 
IV 
  
21 (63,6) 
8 (24,2) 
4 (12,1) 
Multifocal tumor, n (%) 
yes 
no 
 
9 (27,3) 
24 (72,7) 
Type of cancer, n (%) 
ductal invasive carcinoma 
lobular invasive carcinoma 
micro papillary carcinoma  
 
24 (72,7) 
8 (24,2) 
1 (3) 
Treatment characteristics 
Surgery, n (%) 
mastectomy 
conservative surgery 
 
10 (30,3) 
23 (69,7) 
Axillary node dissection, n (%) 
yes 
no 
 
13 (39,4) 
20 (60,6) 
Chemotherapy, n (%)  
20 
 
3 FEC + 3 docetaxel 
6 docetaxel + cyclophosphamide 
31 (94) 
2 (6) 
Type of endocrine therapy at T3 
Letrozol 
Anastrozol 
Exemestane 
Tamoxifen 
 
15 (45,5) 
13 (39,4) 
4 (12,1) 
1 (3) 
Median duration of endocrine therapy (years) [min; 
max] 
3,1 ± 0,6 [1,81; 4;51] 
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Table 2 
 
Period 
Body Composition 
T0 - T3 T2 - T3 
mean SD p mean SD p 
Weight (Kg) 
      
Overall population (n= 33) 2,0 5,4 0,031 2,0 5,5 0,04 
Normal fat mass (n=16) 1,5 4,7 0,22 0,06 4,8 0,96 
Overfat/obese (n=17) 2,5 5,9 0,094 3,8 5,6 0,012 
Waist circumference (cm) 
      
Overall population (n=29) 4,8 8 0,0032 3,3 8 0,021 
Normal fat mass (n=15) 1,3 6,4 0,45 -0,66 6,1 0,68 
Overfat/obese (n=14) 8,5 7,8 0,0013 7,5 7,5 0,0017 
Total Fat Mass (Kg, DEXA) 
      
Overall population (n= 33) 0,9 3,8 0,17 1,78 3,8 0,0073 
Normal fat mass (n=16) 1,0 3,9 0,32 0,74 3,7 0,45 
Overfat/obese (n=17) 0,8 3,7 0,38 2,8 3,5 0,0054 
Trunk Fat Mass (Kg, DEXA) 
      
Overall population (n= 33) 0,7 2,2 0,063 1,4 2,2 0,00031 
Normal fat mass (n=16) 0,6 2,1 0,27 0,6 2 0,27 
Overfat/obese (n=17) 0,8 2,2 0,16 2,2 2 0,00067 
Total Lean Body Mass (Kg, DEXA) 
     
Overall population (n= 33) 1,5 3,2 0,0083 0,8 2 0,035 
Normal fat mass (n=16) 0,9 2,5 0,18 0,2 1,9 0,63 
Overfat/obese (n=17) 2.1 3,7 0,034 1,4 2,2 0,024 
Trunk Lean Body Mass (Kg, DEXA) 
    
Overall population (n= 33) 0,9 2 0,015 0,75 1,6 0,01 
Normal fat mass (n=16) 0,4 1,5 0,3 0,1 1,4 0,69 
Overfat/obese (n=17) 1,3 2,3 0,034 1,4 1,6 0,0048 
Total Body Water (Kg, Impedance) 
     
Overall population (n= 29) 0,8 2,5 0,082 0,8 2 0,036 
Normal fat mass (n=15) 1,0 2,2 0,11 0,3 2,3 0,65 
Overfat/obese (n=14) 1,6 2,7 0,39 1,4 1,6 0,0052 
Bone mineral content (g, DEXA) 
      
Overall population (n= 31) 1,0 4,5 0,2 1,1 4,6 0,19 
Normal fat mass (n=15) 0,96 4,3 0,39 0,97 4,3 0,39 
Overfat/obese (n=17) 1,1 4,7 0,37 1,2 4,9 0,36 
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FIGURES 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  
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Figure 4 
 
a. Body composition of normal fat mass subgroup (N=16) 
 
b. Body composition of overfat/obese subgroup (N=17) 
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